Stocktoria
Sol-Gel Technologies Ltd. SLGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-02-01
Sol-Gel Technologies Ltd. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $19.4M | $11.5M | $1.6M | $3.9M | $31.3M |
| R&D expense | $22.8M | $17.8M | $23.5M | $12.7M | $20.4M |
| Operating income | -$7.5M | -$12.0M | -$29.3M | -$16.2M | $3.0M |
| Income tax | $0 | $0 | $0 | — | $0 |
| Net income | -$6.1M | -$10.6M | -$27.2M | -$14.9M | $3.2M |
| EPS (diluted) | $-2.19 | $-3.79 | $-10.01 | $-0.65 | $0.14 |
| Operating cash flow | $322,000 | -$13.9M | -$17.7M | -$9.5M | -$7.7M |
| Free cash flow | $275,000 | -$13.9M | -$17.9M | -$9.7M | -$7.8M |
| Cash & equivalents | $11.0M | $19.5M | $7.5M | $12.4M | $20.1M |
| Total assets | $29.9M | $35.8M | $45.3M | $46.6M | $69.2M |
| Total liabilities | $7.1M | $7.0M | $6.6M | $4.4M | $13.6M |
| Shareholders' equity | $22.8M | $28.9M | $38.6M | $42.2M | $55.6M |
Source: SEC EDGAR filings · CIK 0001684693 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.